Olmesartan
- Generic Name
- Olmesartan
- Brand Names
- Azor, Benicar, Benicar Hct, Olmetec, Olmetec Plus, Tribenzor
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N6O3
- CAS Number
- 144689-24-7
- Unique Ingredient Identifier
- 8W1IQP3U10
- Background
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, valsartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02848170
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 504
- Registration Number
- NCT02516826
- Locations
- π°π·
Cardiac and Vascular Center; Samsung Medical Center, Seoul, Korea, Republic of
Fimasartan Achieving SBP Target (FAST) Study
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 369
- Registration Number
- NCT02495324
- Locations
- π°π·
The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
π°π·The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
π°π·The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of
RAS Peptide Profiles in Patients With Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 107
- Registration Number
- NCT02449811
- Locations
- π¨π
University Hospital, Basel, Switzerland
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT02407210
- Locations
- π¨π³
Beijing ANZHEN Hospital, Beijing, China
Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 1
- Registration Number
- NCT02373462
- Locations
- π°π·
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Seoul, Korea, Republic of
Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Central South University
- Target Recruit Count
- 12
- Registration Number
- NCT01907373
- Locations
- π¨π³
Center of New Drug Clinical Trial, Hunan Provincial Tumor Hospital (The Affiliated Tumor Hospital of Xiangya Medical School of Central South University), Changsha, Hunan, China
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
- Conditions
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT01876368
- Locations
- πͺπΈ
Novartis Investigative Site, Madrid, Spain
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 115
- Registration Number
- NCT01870739
- Locations
- π¬π§
Novartis Investigative Site, Glasgow, Scotland, United Kingdom
Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- Severance Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01831479
- Locations
- π°π·
Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.